Esophageal Cancer

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer

By

A clinical trial found a potential marker to identify the patients with advanced esophageal squamous cell carcinoma who were most likely to respond to nivolumab.

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial

By

The study was halted when patient response rates were lower than those seen across a similar trial involving the drug.

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

No Benefit With Addition of EGFR Inhibitor to Chemotherapy in Esophageal Cancer

By

The addition of an EGFR inhibitor to a chemotherapy regimen did not improve outcomes when it came to cancers of the esophagus.

Nodal Response to Neoadjuvant Therapy Predictive of Survival in Esophageal Cancer

Nodal Response to Neoadjuvant Therapy Predictive of Survival in Esophageal Cancer

By

Findings on the predictive nature of nodal response to neoadjuvant therapy from the American Association for Thoracic Surgery 98th Annual Meeting.

Esophageal and Esophagogastric Junction Cancer Treatment Regimens

Find the latest cancer treatment regimens for esophageal and esophagogastric junction cancers, including drugs such as ECF, cisplatin, and 5-FU.

Hot tea consumption associated with increased esophageal cancer risk in high-risk individuals

1. Hot tea consumption in combination with excessive smoking or alcohol use was associated with a higher risk for esophageal cancer. 2. In the absence of excessive alcohol use and smoking, daily tea drinking was not linked to increased risk for esophageal cancer. Evidence Rating Level: 1 (Excellent)      Study Rundown: Esophageal cancer is a concern []

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

Radiotherapy Dose to Lung Affects Overall Survival Among Patients With Esophageal Cancer

By

Researchers evaluated the outcomes of 453 patients with stage I to III esophageal cancer who received definitive or preoperative chemoradiation.

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

FLOT Combination Therapy May Be a New Standard for Esophageal Cancer

By

The relative effects of FLOT were demonstrable in all subgroups, and was pronounced numerically in patients with Barrett tumors, small tumors T1/2, nodal negative tumors, and Siewert type 1 esophageal tumors.

Volatile Organic Compounds and Esophageal Cancer: Understanding the Implications for Diagnosis and Treatment

Volatile Organic Compounds and Esophageal Cancer: Understanding the Implications for Diagnosis and Treatment

By

While utilization of VOCs in the early detection of esophageal cancer has shown promise, future studies should aim at determining which VOCs would be the most specific in diagnosing GI malignancies.

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

Adding Pertuzumab Does Not Prolong Overall Survival in HER2+ Gastric or Gastro-esophageal Cancers

By

Though a longer overall survival was observed in patients who received pertuzumab plus trastuzumab and chemotherapy, it was not statistically significant.

Neoadjuvant Cisplatin, Epirubicin, and Capecitabine vs Cisplatin and Fluorouracil for Esophageal Cancer

Neoadjuvant Cisplatin, Epirubicin, and Capecitabine vs Cisplatin and Fluorouracil for Esophageal Cancer

By

Increasing the intensity and duration of neoadjuvant chemotherapy with ECX did not improve survival compared with CF among patients with esophageal adenocarcinoma.

Phase 3 Study of Pembrolizumab in Esophageal and Esophagogastric Junction Cancers

Phase 3 Study of Pembrolizumab in Esophageal and Esophagogastric Junction Cancers

By

For this study, patients will receive pembrolizumab monotherapy or investigator's choice of paclitaxel, docetaxel, or irinotecan.

Bevacizumab and Perioperative Chemotherapy for Esophago-gastric Cancers

Bevacizumab and Perioperative Chemotherapy for Esophago-gastric Cancers

By

Bevacizumab is not recommended in conjunction with perioperative chemotherapy for patients with esophageal adenocarcinoma.

PET Scans Inform, Improve Treatment in Esophageal Cancer

PET Scans Inform, Improve Treatment in Esophageal Cancer

By

Altering chemotherapy during neoadjuvant chemoradiotherapy based on response to induction chemotherapy by PET imaging can improve pathologic complete response.

Docetaxel-based Perioperative Therapy Recommended in Gastric Cancer

Docetaxel-based Perioperative Therapy Recommended in Gastric Cancer

By

Study authors conclude that FLOT should be an internationally standard option for patients with resectable gastric cancer.

Achalasia and the Risk for Esophageal Cancer

Achalasia and the Risk for Esophageal Cancer

By

Some data suggest esophageal cancer may be more common among patients diagnosed with achalasia, but there are no relevant screening guidelines.

Neoadjuvant CRT Improves Survival in Locally Advanced Squamous Cell Esophageal Cancer

Neoadjuvant CRT Improves Survival in Locally Advanced Squamous Cell Esophageal Cancer

By

Adding chemoradiotherapy prior to surgery improves survival versus surgery alone in patients with locally advanced esophageal squamous cell carcinoma (SCC).

Neoadjuvant DCF May Improve RFS in Advanced Esophageal SCC

Neoadjuvant DCF May Improve RFS in Advanced Esophageal SCC

By

Among patients with esophageal squamous cell carcinoma, neoadjuvant treatment with docetaxel, cisplatin, and fluorouracil (DCF) improves survival.

Studies Identify More Risk Loci for Esophageal Adenocarcinoma

Studies Identify More Risk Loci for Esophageal Adenocarcinoma

By

The number of known risk loci for Barrett's esophagus and esophageal adenocarcinoma has doubled.

VSIG10L Gene May Signify Susceptibility to Esophageal Adenocarcinoma

VSIG10L Gene May Signify Susceptibility to Esophageal Adenocarcinoma

By

VSIG10L may be a susceptibility gene for familial syndrome of esophageal adenocarcinoma and Barrett esophagus.

Optimal Chemo Backbone for Metastatic Esophageal Cancer Assessed

Optimal Chemo Backbone for Metastatic Esophageal Cancer Assessed

By

While differences in efficacy between the 3 backbone regimens were nonsignificant, FOLFOX was the best tolerated of tested regimens.

Adding to RT to Neoadjuvant Chemo Improves Response in Esophageal Cancer

Adding to RT to Neoadjuvant Chemo Improves Response in Esophageal Cancer

By

The addition of radiotherapy to neoadjuvant chemotherapy improved histological complete response rate.

VTE May be Risk Factor for Recurrence in Esophageal Cancer

VTE May be Risk Factor for Recurrence in Esophageal Cancer

For patients with esophageal cancer, venous thromboembolism (VTE) is a risk factor for recurrence.

Neoadjuvant CRT Does Not Benefit Patients with cN- Esophageal Adenocarcoma

Neoadjuvant CRT Does Not Benefit Patients with cN- Esophageal Adenocarcoma

By

Those with clinically staged node-negative (cN-) tumors do not derive a significant overall survival benefit vs surgery alone.

Low Education, Income May Increase Risk of Esophageal, Gastric Cancer

Low Education, Income May Increase Risk of Esophageal, Gastric Cancer

By

Divorce, widowhood, living alone, low educational attainment, and low income increase the risk of each subtype of esophageal and gastric cancer.

Quality of Life after Esophagectomy Similar between Older, Younger Patients

Quality of Life after Esophagectomy Similar between Older, Younger Patients

By

Older and younger patients have similar health-related quality of life after esophagectomy for esophageal cancer.

Lymphadenectomy Extent During Esophageal Cancer Surgery May Not Impact Survival

Lymphadenectomy Extent During Esophageal Cancer Surgery May Not Impact Survival

By

The extent of lymphadenectomy during surgery for esophageal cancer might not influence 5-year all-cause or disease-specific survival.

In Resectable Esophageal, EGJ Cancer, Chemoradiotherapy Improves Survival

In Resectable Esophageal, EGJ Cancer, Chemoradiotherapy Improves Survival

By

Neoadjuvant chemoradiotherapy improves overall survival when added to surgery in esophageal or esophagogastric junctional cancer.

Salvage Surgery in the Management of Esophageal Cancer

Salvage Surgery in the Management of Esophageal Cancer

By

Persistent esophageal cancer after definitive chemoradiotherapy has poorer survival when compared with recurrent cancer.

GERD Duration, Other Factors Raise Esophageal Adenocarcinoma Risk

GERD Duration, Other Factors Raise Esophageal Adenocarcinoma Risk

Symptomatic gastroesophageal reflux disease (sGERD) and other factors increase the risk of esophageal adenocarcinoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs